Inhibition of IL6 in rheumatoid arthritis and juvenile idiopathic arthritis

Maja Mircic; Arthur Kavanaugh

doi:10.1016/j.yexcr.2011.02.017

Inhibition of IL6 in rheumatoid arthritis and juvenile idiopathic arthritis

Exp Cell Res. 2011 May 15;317(9):1286-92. doi: 10.1016/j.yexcr.2011.02.017. Epub 2011 Mar 22.

Authors

Maja Mircic¹, Arthur Kavanaugh

Affiliation

¹ The University of California, San Diego, CA, USA.

PMID: 21439276
DOI: 10.1016/j.yexcr.2011.02.017

Abstract

A number of clinical trials have been done to investigate the role of interleukin-6 (IL-6) as a potential therapeutic target in rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). Most of the data testing this comes from trials of the humanized anti Il-6 receptor antibody tocilizumab. Results from clinical trials worldwide have been promising so far. Additional study will define the ultimate role of tocilizumab and Il6 inhibitors in the treatment paradigms for RA and JIA.

Publication types

Review

MeSH terms

Arthritis, Juvenile / drug therapy*
Arthritis, Juvenile / immunology
Arthritis, Rheumatoid / drug therapy*
Arthritis, Rheumatoid / immunology
Clinical Trials as Topic
Humans
Interleukin-6 / antagonists & inhibitors*
Interleukin-6 / immunology
Receptors, Interleukin-6 / immunology

Substances

Interleukin-6
Receptors, Interleukin-6